BROOMFIELD - Corgenix Medical Corp. in Broomfield is partnering with Eli Lily and Co. to develop diagnostic tests that would measure the effectiveness of certain cancer drugs developed by Lily.

The two companies will collaborate to advance diagnostic technology originally developed by Lilly (NYSE: LLY).

The financial terms of the agreement were not disclosed.

"This relationship strengthens our company's program of strategic alliances in key areas of laboratory and research medicine," said Douglass Simpson, president and chief executive of Corgenix "The Lilly collaboration in particular opens a new door for Corgenix as we continue to explore this technology in global clinical research as potential new technology to meet the needs of oncology clinicians worldwide."